ELVN
Price
$19.20
Change
+$0.01 (+0.05%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.14B
43 days until earnings call
NUVL
Price
$79.53
Change
-$1.55 (-1.91%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
5.85B
43 days until earnings call
Interact to see
Advertisement

ELVN vs NUVL

Header iconELVN vs NUVL Comparison
Open Charts ELVN vs NUVLBanner chart's image
Enliven Therapeutics
Price$19.20
Change+$0.01 (+0.05%)
Volume$13.25K
Capitalization1.14B
Nuvalent
Price$79.53
Change-$1.55 (-1.91%)
Volume$2.1K
Capitalization5.85B
ELVN vs NUVL Comparison Chart in %
Loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVN vs. NUVL commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a Hold and NUVL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ELVN: $19.19 vs. NUVL: $81.08)
Brand notoriety: ELVN and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVN: 91% vs. NUVL: 72%
Market capitalization -- ELVN: $1.14B vs. NUVL: $5.85B
ELVN [@Biotechnology] is valued at $1.14B. NUVL’s [@Biotechnology] market capitalization is $5.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ELVN’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than ELVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 3 TA indicator(s) are bullish while NUVL’s TA Score has 7 bullish TA indicator(s).

  • ELVN’s TA Score: 3 bullish, 6 bearish.
  • NUVL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than ELVN.

Price Growth

ELVN (@Biotechnology) experienced а +4.12% price change this week, while NUVL (@Biotechnology) price change was +3.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

ELVN is expected to report earnings on Nov 06, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.85B) has a higher market cap than ELVN($1.14B). NUVL YTD gains are higher at: 3.577 vs. ELVN (-14.711). ELVN has higher annual earnings (EBITDA): -113.93M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. ELVN (491M). ELVN (0) and NUVL (0) have equivalent revenues.
ELVNNUVLELVN / NUVL
Capitalization1.14B5.85B19%
EBITDA-113.93M-362.01M31%
Gain YTD-14.7113.577-411%
P/E RatioN/AN/A-
Revenue00-
Total Cash491M1.01B49%
Total Debt580KN/A-
TECHNICAL ANALYSIS
Technical Analysis
ELVNNUVL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHUKX39.830.02
+0.05%
JPMorgan Emerging Markets Equity R4
GCEDX10.12N/A
N/A
Goldman Sachs Clean Energy Income Ins
TIGCX22.40-0.04
-0.18%
Thornburg International Growth C
GGEAX25.24-0.07
-0.28%
Nationwide Global Sust Eq A
MNDBX16.18-0.12
-0.74%
MFS New Discovery B

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with SYRE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
-3.66%
SYRE - ELVN
53%
Loosely correlated
+4.77%
NUVL - ELVN
51%
Loosely correlated
+2.76%
CRNX - ELVN
51%
Loosely correlated
+6.35%
DNLI - ELVN
50%
Loosely correlated
-2.03%
XNCR - ELVN
49%
Loosely correlated
-0.67%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.76%
XENE - NUVL
59%
Loosely correlated
-0.11%
CGON - NUVL
58%
Loosely correlated
-0.92%
IDYA - NUVL
57%
Loosely correlated
+0.04%
RVMD - NUVL
57%
Loosely correlated
-0.46%
NRIX - NUVL
57%
Loosely correlated
-2.25%
More